Clinical Observation Of Jinlida Granule Combined With Acarbose On Patients With Impaired Glucose Tolerance

Objective:This project is based on the view of treating impaired glucose tolerance from the spleen,to observe the clinical effect of Jinlida granule combined with acarbose in the treatment of impaired glucose tolerance(IGT)according to the basic pathogenesis characteristics of impaired spleen function.And to further explore the mechanism of Jinlida granule in the treatment of impaired glucose tolerance,so as to provide scientific basis for the treatment of impaired glucose tolerance.Methods:Patients with impaired glucose tolerance who visited the Department of Endocrinology,Affiliated Hospital of Shandong University of traditional Chinese medicine from December 2019 to September 2020,select 60 patients who met the inclusion for the study.Patients were randomly divided into two groups according to the order of visit,there were 30 cases in the treatment group and 30 cases in the control group.The control group was treated with acarbose on the basis of conventional treatment,the control group was treated with acarbose on the basis of conventional treatment,the treatment group was treated with Jinlida Granule on the basis of the control group.The test period was 12 weeks.To observe the normal reversal rate of glucose tolerance,conversion rate of glucose tolerance,reduced maintenance rate,and the scores of quantitative changes of diabetes laboratory indicators and syndromes in 2 groups before and after treatment.And evaluate the respective efficacy of the two groups.Results:1.There were no significant differences in age,gender,BMI,and laboratory indicators between the two groups before treatment(P>0.05).The two sets of data are comparable.2.In terms of clinical trial research,studies have shown thatboth the treatment and control groups prevented patients with impaired glucose tolerance from progressing to diabetes.And the improvement of glucose tolerance in the treatment group was superior to that in the control group.Meanwhile,the levels of FPG,2HPG,TC,TG,LDL-C and BMI in patients with impaired glucose tolerance could be decreased in both groups(P<0.01,P<0.05).Compared with the control group,the treatment group had better effect in reducing FPG,2HPG and TC levels(P<0.01,P<0.05).The treatment group also had the effect of increasing the level of HDL-C,and the difference was statistically significant(P<0.01).3.In terms of the evaluation of the efficacy of TCM syndromes,the curative effect of treatment group is better than that of control group,the difference was statistically significant(P<0.01).Conclusion:Jinlida granules can effectively prevent patients with impaired glucose tolerance from progressing to diabetes,and improve the blood sugar and blood lipid levels of patients with impaired glucose tolerance,and it has no obvious toxic and side effects.There is no obvious adverse reaction when combined with acarbose.Its mechanism of action may be related to the protection of islet β cell function and improvement of insulin resistance.It is confirmed that Jinlida granule is an effective prescription for clinical treatment of impaired glucose tolerance,and it has no obvious effect when combined with acarbose It is worth further promotion.